OncoMatch/Clinical Trials/NCT04895709
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Is NCT04895709 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including BMS-986340 and BMS-936558-01 for cervical cancer.
Treatment: BMS-986340 · BMS-936558-01 · Docetaxel — The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Cervical Cancer
Gastric Cancer
Esophageal Carcinoma
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Urothelial Carcinoma
Pancreatic Cancer
Melanoma
Ovarian Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care therapies
Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated.
Cannot have received: docetaxel (docetaxel)
Exception: Part 1C only
participants with prior docetaxel use for the advanced/metastatic setting will be excluded (Part 1C)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Community Cancer Institute · Clovis, California
- USC/Norris Comprehensive Cancer Center · Los Angeles, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- Local Institution - 0062 · Iowa City, Iowa
- John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04895709 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior docetaxel disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages